Batimastat (BB-94) is primarily used in research and clinical studies as a matrix metalloproteinase (MMP) inhibitor. Its application is significant in the field of cancer research, where it is studied for its potential to inhibit tumor growth and metastasis by blocking the activity of MMPs, which are enzymes involved in the breakdown of extracellular matrix components. This action can help prevent the spread of cancer cells to other parts of the body.

In addition to oncology, Batimastat is also explored in the context of inflammatory diseases and conditions where tissue remodeling is a key factor. For example, it has been investigated for its potential to reduce inflammation and tissue damage in diseases such as arthritis and certain cardiovascular conditions.

Furthermore, Batimastat has been used in experimental models to study wound healing and fibrosis, as MMPs play a role in these processes. By inhibiting MMPs, Batimastat can help researchers understand the mechanisms behind tissue repair and the development of fibrotic tissue.

Overall, Batimastat serves as a valuable tool in biomedical research, providing insights into the role of MMPs in various diseases and conditions, and offering potential pathways for therapeutic intervention.